Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q15661

UPID:
TRYB1_HUMAN

ALTERNATIVE NAMES:
Tryptase I; Tryptase alpha-1

ALTERNATIVE UPACC:
Q15661; D2E6R9; D2E6S1; P15157; Q15663; Q6B052; Q9H2Y4; Q9H2Y5; Q9UQI1

BACKGROUND:
Tryptase alpha/beta-1, identified by alternative names Tryptase I and Tryptase alpha-1, serves as the major neutral protease secreted by mast cells upon activation. It is implicated in the innate immune response, with different isoforms exhibiting varied substrate specificity. Isoform 2, in particular, is noted for its enhanced ability to cleave larger molecules such as fibronectin.

THERAPEUTIC SIGNIFICANCE:
The exploration of Tryptase alpha/beta-1's function offers a promising avenue for the development of novel therapeutic approaches. Given its crucial role in mast cell degranulation and the innate immune system, targeting this protease could lead to innovative treatments for a range of immune-mediated conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.